Thank you for Subscribing to Life Science Review Weekly Brief
The company’s equity and capital would be tripled as a result of these funds. It will allow CVasThera to fund preclinical trials for its CVT120165 molecule, which is a Crohn’s disease drug candidate.
FREMONT, CA: CVasThera, a biopharmaceutical firm specializing in the advancement of new treatments for cardiovascular and bowel diseases, announced today that it has raised 1.3 million dollars ($1.6 million) in the first round of Funding. The company’s equity and capital would be tripled as a result of these funds. It will allow CVasThera to fund preclinical trials for its CVT120165 molecule, which is a Crohn’s disease drug candidate. Safety results from phase I trials with healthy subjects, which were completed in 2008 for another indication, are already available. In 2022, the firm intends to go forward with a pilot phase II experiment with Crohn’s patients.
The company’s primary investor is OCSEED, a venture capital firm based in France’s Occitanie region that is making its first investment in the company. In the form of convertible bonds, this infusion of funds would provide CVasThera with the equity funding it wants to go forward with clinical trials and expand its pharmaceutical research and development team. The remaining funds will come from the company’s investors, who will contribute long-term and working capital, as well as a Bpifrance investment loan, financing from the Occitanie region, and a partnership with the French National Research Agency.
Corticosteroids are the treatment of choice for Crohn’s patients with mild to serious flare-ups. However, there are a variety of risks to these medications that hinder their use. There is a substantial medical need for a therapy that will eliminate inflammatory flare-ups and restore the structural damage to the intestine lining of early-diagnosed Crohn’s patients, in addition to corticosteroids.
CVasThera’s lead drug candidate is a game-changing breakthrough that has the potential to close a critical void in the therapeutic arsenal for Crohn’s disease. Rather than rebuilding the weakened intestinal tissue, most current therapies aim to reduce the inflammatory response. The CVT120165 compound, on the other hand, has a special mechanism of action that restores intestinal tissue damage and relieves patients’ painful symptoms. Perhaps more novel is the fact that the compound directly attacks the damaged tissue.
The molecule is stored in a proprietary capsule that allows the drug to be reabsorbed and adhered to weakened tissue in the intestine. This combination of two supplementary mechanisms repair and targeted treatment makes CVT120165 an up-and-coming option for Crohn’s patients.
While several firms are focused on new approaches to mitigate inflammatory flare-ups, the CVasThera project is the only one that aims to reverse the disease’s tissue damage. It’s still the only PAR-1 antagonist in clinical trials for curing Crohn’s flare-ups and avoiding relapses. According to CVasThera’s figures, Crohn’s disease patients represent a 4 billion dollars (3.3 billion) industry in the United States and Europe, which is rising at a rate of 0.3 percent per year. The disease’s diagnosis and prevalence rates are also growing at a fast pace.